Nama's AI scorecard currently rates Liquidia Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is LQDA's P/E ratio?

Liquidia trades at a trailing price-to-earnings ratio of 32.4.

When does LQDA report earnings?

Liquidia's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.98.

What is the LQDA price target?

The median analyst price target from 8 analysts is $56.50, with a range of $33.00 – $70.00.

Is LQDA Shariah compliant?

Nama's AAOIFI-style screen reads Liquidia as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Liquidia (LQDA)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Liquidia (LQDA) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $3.97B, a trailing price-to-earnings ratio of 32.4 and a free-cash-flow yield of -1.1%. Over the most recent reported fiscal year, revenue grew 1031.2%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 6.5/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +4.2% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-52.6%

How far the last close sits under the highest price of the past five years.

Market cap	$3.97B
Trailing P/E	32.4
Price / book	20.3
Price / sales	8.8
FCF yield	-1.1%
Dividend yield	—
Gross margin	92.5%
Operating margin	37.4%
Net margin	30.7%
Revenue growth (YoY)	+1031.2%
Revenue growth (3-yr annual)	+115.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

LQDA earnings

Next report: Nov 10, 2026 (Q3 2026, EPS estimate $0.98). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 12, 2026	$0.74	$0.85	-12.9%	$171.68M
Q1 2026	May 11, 2026	$0.52	$0.40	+30.0%	$132.87M
Q4 2025	Mar 5, 2026	$0.15	$0.33	-54.5%	$92.02M
Q3 2025	Nov 3, 2025	-$0.04	-$0.35	+88.6%	$54.34M

LQDA analyst price target

Median target $56.50 from 8 analysts, ranging $33.00 – $70.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live LQDA data on Nama Insights →

LQDA FAQ

Is LQDA a buy?: Nama's AI scorecard currently rates Liquidia Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LQDA's P/E ratio?: Liquidia trades at a trailing price-to-earnings ratio of 32.4.
When does LQDA report earnings?: Liquidia's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.98.
What is the LQDA price target?: The median analyst price target from 8 analysts is $56.50, with a range of $33.00 – $70.00.
Is LQDA Shariah compliant?: Nama's AAOIFI-style screen reads Liquidia as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.